Landscape Capital Management L.L.C. Invests $1.32 Million in Pfizer Inc. (NYSE:PFE)

Landscape Capital Management L.L.C. bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 45,583 shares of the biopharmaceutical company's stock, valued at approximately $1,319,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Olistico Wealth LLC acquired a new position in Pfizer in the second quarter valued at $25,000. Gladius Capital Management LP grew its holdings in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares during the period. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP purchased a new position in Pfizer in the second quarter valued at approximately $31,000. Finally, Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter valued at approximately $34,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 2.0 %

Shares of PFE traded up $0.50 during trading hours on Friday, hitting $25.63. 41,859,420 shares of the stock traded hands, compared to its average volume of 38,489,203. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $145.24 billion, a PE ratio of 34.64, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67. The business has a fifty day moving average of $28.21 and a 200-day moving average of $28.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.55%. Pfizer's dividend payout ratio (DPR) is presently 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company's stock, valued at $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Daiwa Capital Markets upgraded Pfizer from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a "market perform" rating and a $32.00 price target for the company. Finally, Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.